Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 3069 2022-11-13 07:46:25 |
2 Format correction Meta information modification 3069 2022-11-14 01:57:02 | |
3 table format Meta information modification 3069 2022-11-14 02:03:11 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Alser, M.;  Elrayess, M.A. Fat Redistribution. Encyclopedia. Available online: (accessed on 30 November 2023).
Alser M,  Elrayess MA. Fat Redistribution. Encyclopedia. Available at: Accessed November 30, 2023.
Alser, Maha, Mohamed A. Elrayess. "Fat Redistribution" Encyclopedia, (accessed November 30, 2023).
Alser, M., & Elrayess, M.A.(2022, November 13). Fat Redistribution. In Encyclopedia.
Alser, Maha and Mohamed A. Elrayess. "Fat Redistribution." Encyclopedia. Web. 13 November, 2022.
Fat Redistribution

Type 2 diabetes (T2D) is a chronic condition where the body is resistant to insulin leading to an elevated blood glucose state. Obesity is a main factor leading to T2D. Many clinical studies, however, have described a proportion of obese individuals who express a metabolically healthy profile, whereas some lean individuals could develop metabolic disorders. To study obesity as a risk factor, body fat distribution needs to be considered rather than crude body weight. Different individuals’ bodies favor storing fat in different depots; some tend to accumulate more fat in the visceral depot, while others tend to store it in the femoral depot. This tendency relies on different factors, including genetic background and lifestyle. Consuming some types of medications can cause a shift in this tendency, leading to fat redistribution. Fat distribution plays an important role in the progression of the risk of insulin resistance (IR). Apple-shaped individuals with enhanced abdominal obesity have a higher risk of IR compared to BMI-matched pear-shaped individuals who store their fat in the gluteal-femoral depots. This is related to the different adipose tissue physiology between these two depots. In this text, the recent evidence showing antidiabetic drugs that impact fat distribution as they manage the T2D condition is summarized. 

diabetes obesity body fat composition fat depot abdominal subcutaneous fat gluteal-femoral subcutaneous fat

1. Introduction

Type 2 diabetes (T2D) is a chronic health condition where the blood glucose level is elevated. T2D is a consequence of insulin resistance (IR), where the body cells are irresponsive to insulin and unable to absorb glucose from the blood. IR is associated with the development of dyslipidemia and inflammation in the affected individuals [1]. Dyslipidemia is defined as a state of imbalance in blood lipids, including elevated levels of triglycerides, smaller and denser low-density lipoprotein than normal, and lower high-density lipoprotein levels [2]. IR also causes high blood pressure and glucose intolerance, which leads, with other factors, to T2D progression [3].
One of the major risk factors for IR and T2D is obesity. Obesity-related T2D has become a global pandemic. It is estimated that affected patients with obesity-associated T2D will reach 300 million by 2025 [4]. This is primarily due to the transition to a more sedentary life in specific countries [5]. Although the relationship between obesity and IR is well established, the causal relationship between obesity and IR, among other metabolic disorders, is more complex. Clinical studies have shown that between 10% and 40% of obese individuals (having a body mass index (BMI) > 30), in fact, are metabolically healthy and exhibit normal insulin sensitivity [6]. On the other hand, both lean and overweight individuals are mostly insulin sensitive, but some can develop metabolic disorders including IR [7]. The explanation for lean individuals developing a metabolically obese state may lie in the body fat content and fat distribution [8].
Body fat content and fat distribution is identified as the total body content of adipose tissue (AT). This specialized tissue is a connective tissue consisting of specialized cells called adipocytes and other types of cells. The health of AT is critical in terms of metabolic disorders, as it plays essential metabolic roles as will be discussed in Section 2 [9]. Dysfunctional AT can cause different pathologies and metabolic diseases, including IR and cardiovascular disorders (CVDs). It is known that AT is not a fixed organ that grows in one specific location, but rather distributed in different locations in the body. These variations are called adipose tissue depots [10]. Different individuals tend to have different fat distribution, as their bodies accumulate fat in different depots more than in other depots. This variation is due to differences in their genetic background or environmental factors, such as diet and exercise [11].
AT is deposited in different depots, mainly abdominal and peripheral. Abdominal fat is classified as either subcutaneous or as visceral fat, while peripheral fat is the subcutaneous fat stored in the body’s peripheries, mainly gluteal-femoral fat. Different depots have different functions, and the ratio between these depots plays a major role in health and disease in a more specific way than total body fat content. Previous research has laid the foundation for different depots and differences in their anatomy, physiology, and pathophysiology, as well as their associations with metabolic disorders [12][13][14]. Abdominal fat accumulation is highly associated with the risk of metabolic disorders, whereas gluteal-femoral fat has been shown to have a protective effect against these disorders. In order to utilize this risk difference in a beneficial way, the fat redistribution concept has been proposed. Fat redistribution could be used with cases having high abdominal fat content. If the accumulated fat is successfully redistributed from the abdominal depot to the gluteal-femoral depot, the risk of developing metabolic disorders could be reversed.

2. Fat Redistribution: A Therapeutic Strategy to Reverse Insulin Resistance

Fat redistribution is the process where fat storage is shifted from one depot to another. In the context of reversing IR and its metabolic complications (T2D and CVDs), fat redistribution from the abdomen to the gluteal-femoral depot is getting researchers’ attention as a potential therapeutic strategy. Some existing compounds/IR medications have been shown to affect the formation of new fat and the process of fat distribution as one of their modes of action, leading to fat gain/loss in diabetes patients. In this section, these compounds and their effect on fat redistribution as a treatment of IR will be reviewed and discussed.

2.1. Thiazolidinedione (TZD)

One important compound used to treat IR and T2D is Thiazolidinedione (TZD), also known as pioglitazone. This medication is used to reverse the IR state and lower blood glucose levels in T2D patients. Previously, it was believed that a major side effect of using TZD for T2D patients is body weight gain. However, some clinical evidence shows that the fat is redistributed in a beneficial direction from visceral to subcutaneous fat depot [15]. Other clinical evidence showed that the increase in body weight after TZD treatment was associated with a neutral/decrease in visceral fat and abdominal obesity [16]. It is important to mention that the use of TZD requires to be monitored closely, especially when prescribed for patients with high risk of cardiac diseases. This is because it can be associated with side effects, including weight gain due to fluid retention rather than fat distribution, which may progress to cause cardiac complications [17].
The mode of action of TZD is mainly through stimulation of the expression of the master regulator of adipogenesis: Peroxisome proliferator-activated receptor gamma (PPARg) [18]. The exact mechanism of TZD for reversing IR is still not fully understood. However, researchers know it induces PPARg-mediated expansion of subcutaneous AT, which leads to a drop in systemic fat content and reverses lipotoxicity resulting from fat storage in ectopic depots [19]. Recent clinical studies have shown that TZD treatment leading to AT expansion may be due to the formation and growth of new adipocytes (hyperplasia) in subcutaneous AT depots [20]. This is consistent with the in vivo findings of de Souza et al., 2001, showing that TZD treatment leads to an increase in the proportion of small adipocyte population in subcutaneous AT (hyperplasia) in lab rats [21]. Another important effect of TZD is its anti-inflammatory action, as it activates anti-inflammatory pathways in obesity-associated AT inflammation [22]. One recent investigation showed a wide characterization of the chronic effect of TZD treatment on human AT. The study showed that the glycerophospholipid pool is a major player in how the AT responds to TZD treatment, emphasizing a potential role of adipose cells membrane remodeling as a target of T2D treatment [9]. The findings about TZD mode of action and effect on fat storage are summarized in Table 1. According to previous studies, redistribution of fat storage from the ectopic and visceral anatomical locations into the newly formed subcutaneous depots exhibits a protective effect against IR and its metabolic complications. However, more studies are needed to show if TZD can be used to redistribute fat into the gluteal-femoral fat depot and the therapeutic effectiveness on reversing IR.
Table 1. Summary of Type 2 diabetes medications, their mechanisms of action, and their effect on total body weight and fat distribution.

2.2. Metformin

Biguanide metformin is one of the most widely used medications for blood–glucose lowering and IS improvement in T2D patients. With its good safety profile, it has become the first-line medication for T2D [42]. Studies have shown a clear effect of metformin on reducing body weight and preventing obesity in T2D patients [43], making it the first candidate drug to be used for obese diabetic patients [44]. The weight-lowering effect of metformin was reported to differ among patients with different BMIs. In lean diabetic patients, metformin does not cause a significant weight loss, whereas in obese patients it does; yet, the underlying mechanism behind this difference is still unclear. Studies have suggested that metformin affects body weight through directly affecting adipogenesis. According to Alexender et al., metformin inhibits adipogenesis in vitro using the murine adipose cell line 3T3L1 [24]. However, limited research was done to assess how metformin regulates the adipogenesis-signaling pathways. Another study showed that metformin, combined with insulin treatment, led to enhanced adipogenesis in vitro [24]. Recent investigations conducted on the 3T3L1 murine cell line showed that metformin at low doses (1.25 and 2.5 mM) significantly induced adipogenesis and fat accumulation in these cells, while higher concentrations (5 and 10 mM) had the opposite effect, as they significantly reduced adipogenesis levels in the cells [42].
Studies involving animal subjects and human subjects suggested that metformin specifically affects visceral fat mass. According to Tokubuchi et al., 2017, metformin reduces visceral fat accumulation compared to controls. This effect may not be caused by fat redistribution from visceral to the gluteal-femoral depot, but rather because it elevates the fat metabolism in that depot [25]. Metformin upregulates fat-oxidation-related enzymes, the uncoupling proteins 1 and 3 (UCP1 and UCP3) indicating increased fat burning as a source of energy, causing visceral total mass reduction. This beneficial effect may be the reason why previous studies reported an effective fat loss after using metformin [25]. These findings are summarized in Table 1. Although it has not been demonstrated, the effect of metformin on the size of gluteal-femoral may be worth investigating as an additional added benefit of metformin on reversing IR.

2.3. Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA)

The glucagon-like peptide-1 receptor agonist (GLP-1RA) is a class of medications used to control T2D. It has led to a significant improvement in glycemic parameters of diabetes patients. The medication functions by activating the GLP-1 receptors in the pancreas, leading to enhanced insulin release, decreased glucagon release, and enhanced glucose homeostasis [26].
This medication shows other effects on obese diabetic patients, as it leads to general weight loss, which is often dealt with as a positive side effect of GLP-1 and similar medications [45]. Different investigations suggested that GLP-1 has an effective effect by inhibiting adipogenesis (antiadipogenic effect) and enhancing lipolysis (prolipolytic effect) [27].
The effect of GLP-1 on fat redistribution was unclear until very recently. According to Morano et al., 2015, GLP-1 reduces the total fat content and BMI of patients. More importantly, the study showed a difference in fat reduction between different depots [31]. GLP-1-treated cohort showed a significant reduction in both subcutaneous and visceral abdominal fat depots, suggesting a selective antiadipogenic and prolipolytic effects of the drug [31]. This effect is occurring as a result of GLP-1 on adipogenesis and adipogenic pathway markers. According to Challa et al., 2012, in vitro GLP-1 treatment on 3T3L1 cells downregulates PPARg, C/EBPb/d, and regulates the AKT pathway [28]. In human cell lines, GLP-1 affects adipocyte differentiation levels and decreases adipogenesis by downregulating lipogenesis genes and upregulating critical genes in lipolysis pathways [30]. Similarly to metformin, GLP-1 was also shown to decrease body weight by enhancing energy metabolism using fat as fuel [30]; however, its effect on the size of gluteal-femoral also remains to be studied. The findings about GLP-1 are summarized in Table 1.

2.4. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2 Inhibitors)

Multiple medications fall under the sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors), such as dapagliflozin and canagliflozin. Dapagliflozin is a T2D medication used either alone or in combination with other drugs such as metformin. It is a selective SGLT-2 inhibitor, a major gut and renal sodium-glucose cotransporter. The mode of action of its glucose-lowering effect is by targeting SGLT2, reducing glucose reabsorption in the kidneys. This allows the high glucose content in the blood to be exerted from the body [32]. Many reports showed the effectiveness of dapagliflozin as an antidiabetic drug, but few recent studies showed the link between its insulin sensitization effect and body fat distribution. According to Merovci et al., 2014, dapagliflozin treatment for two weeks improved the condition of T2D patients and decreased their muscle IR, as compared to placebo control [46]. Another study involved the animal model (rats) that showed a positive effect of dapagliflozin on normal and diabetic rats [47].
A recent study showed that treatment of dapagliflozin for four months led to a significant reduction in total body weight and general fat content of their cohort, with no indication of fat distribution [33]. A more recent study reported the effect of dapagliflozin on blood glucose levels as well as body shape and body fat distribution. According to Sun et al., 2020, the treatment of their study cohort with dapagliflozin in combination with metformin for 12 months was associated with enhanced control of their blood glucose levels, indicating an enhanced IS state. Additionally, the study reported that this treatment slightly reduced waist/hip ratio, which indicates a lower abdominal depot fat content as compared to gluteal-femoral depot [34]. Although the mode of action of dapagliflozin as an inhibitor of SGLT2 inhibitor is not yet clear in terms of body fat distribution, the findings indicate that it might affect fat content by influencing adipogenesis. More studies need to be conducted to clarify how it affects adipogenesis at the molecular level.
Canagliflozin is another member of the SGLT2 inhibitors family of T2D drugs that relies on decreasing glucose reabsorption in the kidney [48]. The effect of canagliflozin therapy on T2D and fat distribution was assessed in a few recent studies. One study showed the effect of canagliflozin for 12 weeks on T2D patients. It showed no effect on waist/hip ratio. However, when comparing the subcutaneous and visceral abdominal depots, the study found a significant change in visceral adipose content as compared to baseline level, as well as to the control group. In addition, other parameters like the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Nitric oxide (NO) were improved after the treatment, which indicates an improved IR state and endothelial function [35]. These effects are similar to the effect of dapagliflozin, as both drugs fall into the same family, although their mode of action related to improving fat content and decreasing visceral fat depot remains unclear. The findings about both SGLT-2 inhibitors are summarized in Table 1.

2.5. Insulin

T2D is characterized by both IR, and in later stages, defected insulin secretion due to beta cell dysfunction [39]. Oral medications are clinically used to manage the IR condition to control the elevated glycemic level. For many patients, however, T2D proceeds to the stage where insulin secretion is not sufficient. Therefore, insulin itself is used as a therapeutic molecule in combination with other oral medications to treat T2D [36]. A rare complication of the use of insulin-injection treatment is lipodystrophy, where the repeated injection of insulin at the same site causes the subcutaneous fat to be damaged and take a retracted scar shape [49].
The association between insulin therapy and increased total body weight is well established [41]. In 1998, a preliminary study showed that insulin treatment in T2D patients leads to increased total body weight due to increased subcutaneous, but not visceral, fat deposition. Gluteal-femoral fat was not assessed in the study [50]. Animal studies conducted on rats confirmed the same effect of insulin treatment on abdominal fat distribution via increasing subcutaneous fat with no change in visceral fat content [38].
Insulin treatment influences adipogenesis-related processes. A study showed that insulin treatment of human-derived adipose stem cells leads to their enhanced proliferation [39]. It also upregulates differentiation into adipocytes via Wnt signaling pathway inhibition and the downstreatm regulation of adipogenesis markers, including PPAR-γ and CEBP-α [39]. These effects do not conclusively prove/disprove the effect of insulin on fat redistribution. Limited research has been conducted on the effect of insulin treatment on adipogenesis, fat distribution, and body shape. No previous studies have shown the effect of insulin treatment in a depot-specific manner, and this area still needs to be explored due to its clinical relevance for T2D patients on insulin injections. The findings about insulin are summarized in Table 1.

2.6. Sulfonylureas

Sulfonylureas are a group of oral medications for T2D, often prescribed as a second line of treatment after metformin medication fails to control the elevated glycemic blood levels [51]. It works by increasing the levels of insulin release from the pancreas if the T2D patient is at a stage where insulin is not sufficiently secreted [51].
Sulfonylureas act by stimulating the beta-cells in the pancreas to enhance the endogenous levels of insulin and manage T2D [40]. Thus, this treatment is associated with weight gain in a similar way to insulin injection. This limits the use of both sulfonylureas and insulin with overweight and obese patients as summarized in Table 1 [41].
No previous research directly connected sulfonylurea treatment with adipogenesis process, body shape, or body fat distribution. However, based on what is known, sulfonylureas increase insulin secretion, which has been shown to enhance adipocyte proliferation and upregulates adipogenesis differentiation [39].


  1. Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018, 17, 122.
  2. Pappan, N.; Rehman, A. Dyslipidemia. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. Available online: (accessed on 18 July 2022).
  3. Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113, 898–918.
  4. Azziz, R.; Woods, K.S.; Reyna, R.; Key, T.J.; Knochenhauer, E.S.; Yildiz, B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004, 89, 2745–2749.
  5. Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.-H.; Stevens, G.A.; et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011, 378, 31–40.
  6. Primeau, V.; Coderre, L.; Karelis, A.D.; Brochu, M.; Lavoie, M.-E.; Messier, V.; Sladek, R.; Rabasa-Lhoret, R. Characterizing the profile of obese patients who are metabolically healthy. Int. J. Obes. 2011, 35, 971–981.
  7. Ortega, F.B.; Lee, D.; Katzmarzyk, P.T.; Ruiz, J.R.; Sui, X.; Church, T.S.; Blair, S.N. The intriguing metabolically healthy but obese phenotype: Cardiovascular prognosis and role of fitness. Eur. Heart J. 2013, 34, 389–397.
  8. Patel, P.; Abate, N. Body Fat Distribution and Insulin Resistance. Nutrients 2013, 5, 2019–2027.
  9. Palavicini, J.P.; Chavez-Velazquez, A.; Fourcaudot, M.; Tripathy, D.; Pan, M.; Norton, L.; DeFronzo, R.A.; Shannon, C.E. The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans. Front. Physiol. 2021, 12, 784391.
  10. Neeland, I.J.; Poirier, P.; Després, J.-P. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation 2018, 137, 1391–1406.
  11. Chait, A.; den Hartigh, L.J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 2020, 7, 22. Available online: (accessed on 12 April 2022).
  12. Okura, T.; Nakata, Y.; Yamabuki, K.; Tanaka, K. Regional Body Composition Changes Exhibit Opposing Effects on Coronary Heart Disease Risk Factors. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 923–992.
  13. Meisinger, C.; Döring, A.; Thorand, B.; Heier, M.; Löwel, H. Body fat distribution and risk of type 2 diabetes in the general population: Are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am. J. Clin. Nutr. 2006, 84, 483–489.
  14. McLaughlin, T.; Lamendola, C.; Liu, A.; Abbasi, F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J. Clin. Endocrinol. Metab. 2011, 96, E1756–E1760.
  15. Scheen, A.J. Combined thiazolidinedione-insulin therapy: Should we be concerned about safety? Drug Saf. 2004, 27, 841–856.
  16. Wilding, J. Thiazolidinediones, insulin resistance and obesity: Finding a balance. Int. J. Clin. Pract. 2006, 60, 1272–1280.
  17. MacIsaac, R.J.; Jerums, G. Clinical indications for thiazolidinediones. Aust. Prescr. 2004, 27, 70–74.
  18. Spiegelman, B.M. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47, 507–514.
  19. Bays, H.; Mandarino, L.; DeFronzo, R.A. Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. J. Clin. Endocrinol. Metab. 2004, 89, 463–478.
  20. White, U.; Fitch, M.D.; Beyl, R.A.; Hellerstein, M.K.; Ravussin, E. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: A randomised controlled trial. Diabetologia 2021, 64, 159–167.
  21. De Souza, C.J.; Eckhardt, M.; Gagen, K.; Dong, M.; Chen, W.; Laurent, D.; Burkey, B.F. Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance. Diabetes 2001, 50, 1863–1871.
  22. Spencer, M.; Yang, L.; Adu, A.; Finlin, B.S.; Zhu, B.; Shipp, L.R.; Rasouli, N.; Peterson, C.A.; Kern, P.A. Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. PLoS ONE 2014, 9, e102190.
  23. Domecq, J.P.; Prutsky, G.; Leppin, A.; Sonbol, M.; Altayar, O.; Undavalli, C.; Wang, Z.; Elraiyah, T.; Brito, J.P.; Mauck, K.F.; et al. Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis. J. Clin. Endocrinol. Metab. 2015, 100, 363–370.
  24. Alexandre, K.B.; Smit, A.M.; Gray, I.P.; Crowther, N.J. Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1. Diabetes Obes. Metab. 2008, 10, 688–690.
  25. Tokubuchi, I.; Tajiri, Y.; Iwata, S.; Hara, K.; Wada, N.; Hashinaga, T.; Nakayama, H.; Mifune, H.; Yamada, K. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS ONE 2017, 12, e0171293.
  26. Shaefer, C.F.; Kushner, P.; Aguilar, R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad. Med. 2015, 127, 818–826.
  27. Manning, P.; Munasinghe, P.E.; Papannarao, J.B.; Gray, A.R.; Sutherland, W.; Katare, R. Acute Weight Loss Restores Dysregulated Circulating MicroRNAs in Individuals Who Are Obese. J. Clin. Endocrinol. Metab. 2019, 104, 1239–1248.
  28. Challa, T.D.; Beaton, N.; Arnold, M.; Rudofsky, G.; Langhans, W.; Wolfrum, C. Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling. J. Biol. Chem. 2012, 287, 6421–6430.
  29. El Bekay, R.; Coín-Aragüez, L.; Fernández-García, D.; Oliva-Olivera, W.; Bernal-López, R.; Clemente-Postigo, M.; Delgado-Lista, J.; Diaz-Ruiz, A.; Guzman-Ruiz, R.; Vázquez-Martínez, R.; et al. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br. J. Pharmacol. 2016, 173, 1820–1834.
  30. Beiroa, D.; Imbernon, M.; Gallego, R.; Senra, A.; Herranz, D.; Villarroya, F.; Serrano, M.; Fernø, J.; Salvador, J.; Escalada, J.; et al. GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK. Diabetes 2014, 63, 3346–3358.
  31. Morano, S.; Romagnoli, E.; Filardi, T.; Nieddu, L.; Mandosi, E.; Fallarino, M.; Turinese, I.; Dagostino, M.P.; Lenzi, A.; Carnevale, V. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: An ultrasonography study. Acta Diabetol. 2015, 52, 727–732.
  32. Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; et al. In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans. Drug Metab. Dispos. 2010, 38, 405–414.
  33. Ghosh, A.; Dutta, K.; Bhatt, S.P.; Gupta, R.; Tyagi, K.; Ansari, I.A.; Venugopal, V.K.; Mahajan, H.; Pandey, R.M.; Pandey, S.; et al. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India. J. Clin. Endocrinol. Metab. 2022, 107, e2267–e2275.
  34. Sun, Y.; Yan, D.; Hao, Z.; Cui, L.; Li, G. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2020, 26, e921891.
  35. Hao, Z.; Sun, Y.; Li, G.; Shen, Y.; Wen, Y.; Liu, Y. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. BMC Endocr. Disord. 2022, 22, 37.
  36. DeFronzo, R.A. Pharmacologic Therapy for Type 2 Diabetes Mellitus. Ann. Intern. Med. 1999, 131, 281–303.
  37. Russell-Jones, D.; Khan, R. Insulin-associated weight gain in diabetes–Causes, effects and coping strategies. Diabetes Obes. Metab. 2007, 9, 799–812.
  38. Skovsø, S.; Damgaard, J.; Fels, J.J.; Olsen, G.S.; Wolf, X.A.; Rolin, B.; Holst, J.J. Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes. Int. J. Obes. 2015, 39, 1531–1538.
  39. Liu, H.; Zhan, Y.-L.; Luo, G.-J.; Zou, L.-L.; Li, Y.; Lu, H.-Y. Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway. Diabetes Metab. Syndr. Obes. Targets Ther. 2020, 13, 3075–3087.
  40. Verhaegen, A.A.; van Gaal, L.F. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In Endotext; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., et al., Eds.;, Inc.: South Dartmouth, MA, USA, 2000. Available online: (accessed on 24 July 2022).
  41. Apovian, C.M.; Okemah, J.; O’Neil, P.M. Body Weight Considerations in the Management of Type 2 Diabetes. Adv. Ther. 2019, 36, 44–58.
  42. Chen, D.; Wang, Y.; Wu, K.; Wang, X. Dual Effects of Metformin on Adipogenic Differentiation of 3T3-L1 Preadipocyte in AMPK-Dependent and Independent Manners. Int. J. Mol. Sci. 2018, 19, 1547.
  43. Pernicova, I.; Korbonits, M. Metformin—Mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014, 10, 143–156.
  44. Desilets, A.R.; Dhakal-Karki, S.; Dunican, K.C. Role of Metformin for Weight Management in Patients without Type 2 Diabetes. Ann. Pharmacother. 2008, 42, 817–826.
  45. Jakab, J.; Miškić, B.; Mikšić, Š.; Juranić, B.; Ćosić, V.; Schwarz, D.; Včev, A. Adipogenesis as a Potential Anti-Obesity Target: A Review of Pharmacological Treatment and Natural Products. Diabetes Metab. Syndr. Obes. Targets Ther. 2021, 14, 67–83.
  46. Merovci, A.; Solis-Herrera, C.; Daniele, G.; Eldor, R.; Fiorentino, T.V.; Tripathy, D.; Xiong, J.; Perez, Z.; Norton, L.; Abdul-Ghani, M.A.; et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Investig. 2014, 124, 509–514.
  47. Han, S.; Hagan, D.L.; Taylor, J.R.; Xin, L.; Meng, W.; Biller, S.A.; Wetterau, J.R.; Washburn, W.N.; Whaley, J.M. Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats. Diabetes 2008, 57, 1723–1729.
  48. Lavalle-González, F.J.; Januszewicz, A.; Davidson, J.; Tong, C.; Qiu, R.; Canovatchel, W.; Meininger, G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013, 56, 2582–2592.
  49. Gentile, S.; On behalf of the AMD-OSDI Injection Technique Study Group; Strollo, F.; Ceriello, A. Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? Diabetes Ther. 2016, 7, 401–409.
  50. Takei, I.; Takayama, S.; Yamauchi, A.; Nakamoto, S.; Kitamura, Y.; Katsukawa, F.; Yamazaki, H.; Saruta, T.; Inoue, S. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: A preliminary report. Eur. J. Clin. Nutr. 1998, 52, 153–154.
  51. Douros, A.; Dell’Aniello, S.; Yu, O.H.Y.; Filion, K.B.; Azoulay, L.; Suissa, S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study. BMJ 2018, 362, k2693.
Subjects: Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : ,
View Times: 841
Revisions: 3 times (View History)
Update Date: 14 Nov 2022